Yes, thank you. You read my mind.
I was hoping someone might ask that question. I have maybe three quick points, being conscious of time. I'll speak in English, since I can speak more quickly.
Concerning the two years it has taken, I listened with interest and I'm encouraged by the fact that the department is now meeting its timelines. But I would emphasize that it is a multi-step process, and there are timelines only for certain parts. So that's improvement, but we found—and it was a large number—almost 50% of the cases took more than two years, when they had to go from evaluation through to the actual communication to the medical professionals and Canadians. We found things such as breakdowns in communication between the different sections, between the people dealing with brand name and generic.
We found as well that quite often there were delays because it was easier to batch a number of label changes, if there were a number of different generics. So I think there are more structural things that will also need to be looked at with regard to that.
I have two other quick points. There's been a lot of discussion on clinical trials today, and a lot of encouraging action. Auditors always reserve judgment until they can go back and re-audit, but encouraging indeed.
The one thing that I think remains the largest gap is the question of the availability of information on specific clinical trials. As we sit here now, you could find many of those clinical trials by going to the FDA site or the European Medicines Agency. So I'm encouraged by the actions that Health Canada's taking, but a gap still exists today in terms of the information Canadians have.
Maybe I'll stop there.